Stock CDMO AVID BIOSERVICES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Avid Bioservices, Inc.

Equities

CDMO

US05368M1062

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
7.35 USD +0.41% Intraday chart for Avid Bioservices, Inc. +15.02% +13.08%
Apr. 24 Avid Bioservices, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
Apr. 19 North American Morning Briefing : Stock Futures -2- DJ

Valuation

Fiscal Period: April 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 268.6 344.5 1,302 831.1 1,129 466.6 - -
Enterprise Value (EV) 1 268.6 344.5 1,302 831.1 1,129 466.6 466.6 466.6
P/E ratio -29.9 x -22.6 x 357 x 7.32 x 1,805 x -28.6 x -315 x 40.8 x
Yield - - - - - - - -
Capitalization / Revenue 5.01 x 5.77 x 13.6 x 6.95 x 7.56 x 3.37 x 2.82 x 2.19 x
EV / Revenue 5.01 x 5.77 x 13.6 x 6.95 x 7.56 x 3.37 x 2.82 x 2.19 x
EV / EBITDA -93.4 x -46 x 83 x 27.3 x 52 x 83.1 x 17.8 x 8.11 x
EV / FCF -20.5 x 171 x 61.1 x -17.7 x -12.5 x -13.2 x 76.6 x 17.8 x
FCF Yield -4.88% 0.58% 1.64% -5.65% -8.02% -7.59% 1.31% 5.62%
Price to Book - - 16.4 x 5.44 x 5.97 x 2.57 x 2.93 x 2.39 x
Nbr of stocks (in thousands) 56,075 56,482 60,829 61,744 62,547 63,480 - -
Reference price 2 4.790 6.100 21.40 13.46 18.05 7.350 7.350 7.350
Announcement Date 6/27/19 6/30/20 6/29/21 6/29/22 6/21/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: April 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 53.6 59.7 95.87 119.6 149.3 138.6 165.5 213.1
EBITDA 1 -2.876 -7.494 15.7 30.43 21.7 5.613 26.18 57.53
EBIT 1 -5.622 -10.58 12.24 15.42 3.601 -17.7 1.118 23.49
Operating Margin -10.49% -17.73% 12.77% 12.89% 2.41% -12.76% 0.68% 11.02%
Earnings before Tax (EBT) 1 -5.34 -10.47 11.21 12.66 2.003 -21.1 -1.972 18.59
Net income 1 -8.901 -15.15 3.318 127.7 0.56 -16.32 -1.518 14.14
Net margin -16.61% -25.38% 3.46% 106.75% 0.38% -11.77% -0.92% 6.64%
EPS 2 -0.1600 -0.2700 0.0600 1.840 0.0100 -0.2567 -0.0233 0.1800
Free Cash Flow 1 -13.1 2.015 21.32 -46.95 -90.52 -35.43 6.09 26.2
FCF margin -24.43% 3.38% 22.24% -39.25% -60.65% -25.55% 3.68% 12.3%
FCF Conversion (EBITDA) - - 135.82% - - - 23.26% 45.55%
FCF Conversion (Net income) - - 642.5% - - - - 185.27%
Dividend per Share - - - - - - - -
Announcement Date 6/27/19 6/30/20 6/29/21 6/29/22 6/21/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: April 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 26.11 31.51 31.23 36.69 34.76 38.02 39.8 37.73 25.4 33.8 41.81 42.14 34.98 41.72 49.7
EBITDA 1 5.18 4.293 5.893 6.188 1.885 7.367 6.265 2.791 -5.972 -1.117 5.504 5.441 1.739 6.121 11.11
EBIT 1 4.153 3.269 1.069 2.735 -2.684 2.718 0.832 -2.163 -11.22 -4 -1.091 -1.054 -4.897 -0.834 3.23
Operating Margin 15.91% 10.38% 3.42% 7.45% -7.72% 7.15% 2.09% -5.73% -44.19% -11.83% -2.61% -2.5% -14% -2% 6.5%
Earnings before Tax (EBT) 1 3.522 2.248 0.587 2.267 -3.242 2.53 0.448 -2.68 -11.89 -7.058 -1.848 -4.052 -7.896 -3.833 0.231
Net income 1 3.522 2.248 115.6 1.564 -1.156 0.461 -0.309 -2.093 -9.509 -6.006 -1.286 -3.039 -5.922 -2.875 0.174
Net margin 13.49% 7.13% 370.2% 4.26% -3.33% 1.21% -0.78% -5.55% -37.44% -17.77% -3.07% -7.21% -16.93% -6.89% 0.35%
EPS 2 0.0600 0.0400 1.650 0.0200 -0.0200 0.0100 - -0.0300 -0.1500 -0.0900 -0.0233 -0.0500 -0.0900 -0.0400 -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 12/7/21 3/8/22 6/29/22 9/6/22 12/6/22 3/13/23 6/21/23 9/7/23 12/7/23 3/6/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: April 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -13.1 2.02 21.3 -46.9 -90.5 -35.4 6.09 26.2
ROE (net income / shareholders' equity) -16.4% - 18.7% 19.2% 0.31% -10.5% -1.8% 11.4%
ROA (Net income/ Total Assets) - - 3.64% 6.97% 0.13% -4.3% -0.8% 5.4%
Assets 1 - - 91.03 1,833 440.6 379.6 189.7 261.9
Book Value Per Share 2 - - 1.310 2.480 3.020 2.860 2.510 3.070
Cash Flow per Share 2 -0.0300 - 0.2500 0.1300 -0.2000 -0.1000 0.1700 0.5800
Capex 1 1.5 3.81 9.86 56.4 77.6 31 7 7.75
Capex / Sales 2.8% 6.39% 10.29% 47.17% 52.01% 22.36% 4.23% 3.64%
Announcement Date 6/27/19 6/30/20 6/29/21 6/29/22 6/21/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Avid Bioservices, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.35 USD
Average target price
12.25 USD
Spread / Average Target
+66.67%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
AVID BIOSERVICES, INC. Stock Avid Bioservices, Inc.
+13.08% 467M
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-8.42% 8.12B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. CDMO Stock
  4. Financials Avid Bioservices, Inc.